We established a diagnostic panel consisting of lncRNA (SOX2OT and ANRIL) and tumor markers (CEA, CYFRA21‐1, and SCCA), which could diagnose NSCLC with superior sensitivity and specificity. This evidence concerns the gene CDKN2B-AS1 and non-small cell lung carcinoma.